Neuron Bio patents two new molecules that enter more efficiently into the brain and avoid neuronal death

The Spanish Patent and Trademark Office (SPTO) has granted Neuron Bio with a patent for two compounds that protect neuronal death and penetrate with high efficiency into the brain, two essential features to be used as treatments that delay the start of Alzheimer’s disease and other neurodegenerative disorders.

The patent protects the use of the compounds, which are internally named NST0076 and NST0078 and have been selected for their anti-inflammatory neuroprotective and antiepileptic capacities. The compounds are potentially effective as treatment for neurodegenerative diseases or disorders of the nervous system, concretely for its application in the Alzheimer’s disease and epilepsy.

Javier Burgos, CEO of the company has made a very positive appraisal of this news and stated, “These compounds have been developed thanks to the expertise accumulated by the researchers of the company after evaluating thousands of potential candidates, using company’s own exclusive drug discovery platform that includes models of this disease in human cells and animal models.”

About Neuron Bio

Neuron Bio develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas.

Its pharma division is mainlydevoted to the search of drugs for the prevention and treatment of neurodegenerative diseases, particularly for the Alzheimer’s disease.

Its diagnostic division develops tools and biomarkers for the diagnosis of human diseases, principally for those of the Central Nervous System as the Alzheimer’s disease.

Its service division develops research projects as well as consultancy services for public institutions and for companies of the pharmaceutical, biotechnological, agro-food and animal health area.

Neuron Bio owns a broad and diverse high value molecule collection, neuroprotective compounds, 9 patent applications (2 of them recently granted by the European Union and other 1 also granted by the US Patent and Trademark Office) and exclusive platforms for drug discovery and development.

Neol Bio, a subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

It has a highly qualified team of researchers with wide experience in R&D and renowned prestige in the sector, who participate actively in numerous scientific projects.

Neuron Bio has facilities in Granada and Madrid connected with university research centers and is quoted on the Alternative Stock Market (MAB) in Spain.